GSTM1 and colorectal carcinoma: The current screening tool, based on the measurement of Hb in feces (FIT test), has demonstrated efficacy in randomized trials; however, data collected of FIT from different population cohorts have pointed out that FIT has low sensitivity for AA, where the diagnostic error was bigger than for healthy individuals or CRC patients.